Search results
Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition
Pharmaceutical Technology· 5 days agoEli Lilly has signed a definitive agreement to acquire Morphic Holding for $3.2bn, expanding its...
Eli Lilly to buy bowel disease drug developer Morphic for $3.2 bln - ET HealthWorld | Pharma
The Economic Times· 6 days agoLondon: Eli Lilly will acquire Morphic Holding for $3.2 billion in cash, the companies said on...
Lilly to buy Morphic in $3B bet on inflammation drug
BioPharma Dive· 6 days agoThe deal would hand Lilly an experimental pill that could one day rival Takeda's blockbuster medicine Entyvio as a treatment for inflammatory bowel...
A London biotech raises $114M to hone a new ADC payload
BioPharma Dive· 6 days agoInvestors Novo Holdings and Abingworth co-led its Series A, with participation from British Patient...
Myricx Bio gains $114m in Series A round to develop NMTi-ADCs
Pharmaceutical Technology· 6 days agoThe capital injection will be channelled into expanding Myricx’s NMTi inhibitor ADC payload...
India set to witness obesity pill revolution? As patents near expiry, pharma giants gear up for...
Financial Express· 6 days agoBlockbuster obesity drugs like Ozempic and Wegovy have become a global sensation. Now the Indian...
African swine flu in Kerala pigs won't spread to humans, says Centre
Business Standard India· 7 days agoAfrican swine flu, currently spreading across a few pig farms in Kerala, is non-zoonotic and will...